Royal Bank of Canada Purchases 6,695 Shares of Jazz Pharmaceuticals PLC $JAZZ

Royal Bank of Canada increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 17.4% during the first quarter, Holdings Channel.com reports. The institutional investor owned 45,251 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,695 shares during the period. Royal Bank of Canada’s holdings in Jazz Pharmaceuticals were worth $8,556,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cardinal Capital Management lifted its stake in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 66 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 0.3% during the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after purchasing an additional 73 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 12.6% in the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 81 shares during the period. Pinnacle Associates Ltd. raised its holdings in shares of Jazz Pharmaceuticals by 0.7% in the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares during the period. Finally, Fifth Third Wealth Advisors LLC lifted its stake in Jazz Pharmaceuticals by 4.4% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock valued at $377,000 after purchasing an additional 85 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research analyst reports. TD Cowen lifted their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $287.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Raymond James Financial reiterated an “outperform” rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a report on Tuesday, August 4th. Finally, Bank of America increased their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $272.74.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total value of $1,517,880.00. Following the completion of the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the sale, the director directly owned 9,680 shares in the company, valued at $2,231,724. This represents a 10.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 19,098 shares of company stock valued at $4,649,786. 4.10% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $256.56 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The company’s 50-day simple moving average is $241.29 and its 200 day simple moving average is $209.80. Jazz Pharmaceuticals PLC has a 52 week low of $109.87 and a 52 week high of $265.05. The company has a market capitalization of $16.65 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same quarter last year, the firm earned ($8.25) EPS. Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.62 earnings per share for the current year.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz’s quarterly revenue reached $1.21 billion, beating consensus expectations of $1.11 billion and increasing 15.5% year over year. Management also raised its 2026 revenue outlook to $4.60 billion-$4.75 billion, supported by its neuroscience and oncology businesses. What Does Jazz Pharmaceuticals Raised Guidance Mean
• Positive Sentiment: The company’s oxybate franchise, including Xywav, continues to post double-digit growth despite generic Xyrem competition, helping support confidence in the upgraded outlook.
• Positive Sentiment: Analyst sentiment has strengthened. Wells Fargo raised its price target to $300 and maintained an overweight rating, while Morgan Stanley lifted its target to $280. Other firms, including JPMorgan, Needham and Bank of America, also maintain bullish ratings or targets above the recent trading range. Wells Fargo Gives Jazz Pharmaceuticals a Buy
• Positive Sentiment: Ziihera, or zanidatamab, remains a potential catalyst, with an FDA decision expected August 25 for first-line gastroesophageal adenocarcinoma. Approval could expand Jazz’s oncology revenue base.
• Positive Sentiment: Recent coverage describes JAZZ as a strong long-term momentum and value candidate, reflecting its improving earnings outlook and stock performance near its 52-week high. Why Jazz Pharmaceuticals Is a Top Momentum Stock
• Neutral Sentiment: Adjusted earnings per share were $5.71, below the $6.18 consensus estimate. The revenue beat and higher guidance offset the earnings miss, but margins and future profitability remain important risks.
• Negative Sentiment: Jazz plans to seek FDA withdrawal of the second-line lurbinectedin, marketed as Zepzelca, indication for small-cell lung cancer. The move removes a potential regulatory catalyst and underscores pressure on the product’s development prospects. Jazz Seeks FDA Withdrawal of Lurbinectedin Indication
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares for approximately $1.52 million. The transaction occurred under a pre-arranged Rule 10b5-1 plan and reduced his position by only 1.64%, making it a limited negative signal. Jazz Pharmaceuticals Director Share Sale

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.